Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer

• Published in: International journal of cancer 2006-03, Vol.118 (6), p.1420-1425
• Main Authors: Rodríguez, Germán, Bilbao, Cristina, Ramírez, Raquel, Falcón, Orlando, León, Laureano, Chirino, Ricardo, Díaz, B. Pilar, Rivero, Juan F., Perucho, Manuel, Díaz‐Chico, B. Nicolás, Díaz‐Chico, Juan C.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Alleles; Biological and medical sciences; Endometrial Neoplasms - genetics; Endometrial Neoplasms - pathology; Female; Female genital diseases; Gene Frequency; Genotype; Gynecology. Andrology. Obstetrics; Humans; Kaplan-Meier Estimate; Male; Medical sciences; Middle Aged; polymorphism; Polymorphism, Genetic; Prognosis; prognostic variable; Receptors, Androgen - genetics; Retrospective Studies; Sequence Analysis, DNA - methods; steroid‐dependent tumor; Trinucleotide Repeat Expansion - genetics; Trinucleotide Repeats - genetics; Tumors
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.21516

The human androgen receptor (AR) gene possesses 2 trinucleotide repeats of CAG and GGN in exon 1. The CAG repeat corresponds to a polyglutamine tract in the N‐terminal region of the receptor, that affects its transcriptional efficiency. The GGN repeat codifies for a polyglycine tract, and affects the amount of the AR protein transcribed. The endometrium contains ARs and the androgens have antiproliferative properties in cultured endometrial cancer (EC) cells. Larger CAG repeats of the AR gene give rise to a weaker transcriptional activity and have been found to be associated with endometrial carcinogenesis. The possible involvement of CAG and GGN tracts in the progression of EC is unknown. To study that possibility, we have genotyped both CAG and GGN polymorphisms of the AR gene in tumor tissue genomic DNA from a series of 204 consecutive patients with EC, and analyzed the results with regard to the pathological features and clinical outcome of patients. We classified the alleles as S (short ≤ median; S‐CAG ≤21 repeats; S‐GGN ≤22 repeats) or L (long > median). The genotype with both S‐CAG repeat alleles (SS‐CAG) was more common in patients diagnosed at an early stage (41.6% SS‐CAG vs 22.6% SL‐ and LL‐CAG together, p = 0.048) and in tumors that did not invade the vascular space (43.0% SS‐CAG vs 26.4% SL‐ and LL‐CAG together, p = 0.034). The genotype with SS‐GGN alleles was more common in well‐differentiated tumors (41.2% SS‐GGN vs 25.2% LS‐ and LL‐GGN together, p = 0.017) and in endometrioid histological subtype tumors (35.3% SS‐GGN vs 13.0% SL‐ and LL‐GGN together, p = 0.034). When the genotypes of both repeats coexisting in each tumor specimen were taken into consideration, the relationship between the SS‐CAG genotype and early stage remained only in the presence of the SS‐GGN genotype (43.9% vs 0%, p = 0.01). No other associations were observed. In univariate survival analysis, patients with short alleles of both repeats (SS‐CAG and SS‐GGN genotypes simultaneously) had a lower risk of cancer‐specific death (p = 0.032, mean follow‐up: 63 months). Our data suggests that short CAG or GGN repeats of the AR gene are associated with a more benign condition of traditional prognostic variables in EC. © 2005 Wiley‐Liss, Inc.